|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
����,������ |
|
���� |
|
HIV |
| ��������������� | |
|
������ |
|
������ |
|
�ｨ�� |
| PubMed | |
|
Article by ������ |
|
Article by ������ |
|
Article by �ｨ�� |
���̲������Kaposi�������ƽ�չ
������1, ������2, �ｨ��2
1. ɽ��ʡΫ����Ƥ���������� 261041;
2. �й�ҽѧ��ѧԺ���й�Э��ҽ�ƴ�ѧƤ�����о���
Kaposi��������������ȱ�ݲ�����Ⱦ������Ķ�������,���������ŶԱ����������ƵĽ�һ����ʶ,������һЩ�µ�����ҩ�Ｐ�������ۺ����������ư��̲������Kaposi�������µ�ҩ�Ｐ�Ʒ�,��������������ȱ�ݲ���ҩ����ͻ���ҩ���Ѫ������ҩ�άA�ᡢ�Լ����Լ��������ҩ��ȵ���Ч�Ͳ�����Ӧ��
1. ɽ��ʡΫ����Ƥ���������� 261041;
2. �й�ҽѧ��ѧԺ���й�Э��ҽ�ƴ�ѧƤ�����о���
1. ɽ��ʡΫ����Ƥ���������� 261041;
2. �й�ҽѧ��ѧԺ���й�Э��ҽ�ƴ�ѧƤ�����о���
[2] Dupin N, Rubin De Cervens V, Gorin I, et al. The influence of highly active antiretroviral therapy on AIDS-associated Kaposi's sarcoma.Br J Dermatol, 1999, 140:875-881.
[3] Dupont C, Vasseur E, Beauchet A, et al. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. Centre d'information et de soins de l��immunodeficience humaine. AIDS, 2000, 14:987-993.
[4] Northfelt DW, Dezube B J, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase �� clinical trial. J Clin Oncol, 1998, 16:2445-2451.
[5] Welles L, Saville MW, lietzau J,et al. Phase �� trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. J Clin Oncol, 1998, 16:1112.
[6] Dezube BJ, Von Roenn JH, Holen-Wiltse J,et al. Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team. J Clin Oncol, 1998, I: 1444-1449.
[7] Eckhardt SG, Burris HA, Eckardt JR, et al. A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium. Ann Oncol, 1996, 7:491-496.
[8] Little RF, Wyvill KM, Pluda JM, et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol, 2000, 18:2593.
[9] Tulpule A, Scadden DT, Espina BM, et al. Results of a randomized tudy of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol, 2000, 18:716-723.
[10] Miles SA, Dezube BJ, Lee JY, et al. Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi's sarcoma. AIDS, 2002,16:421-429.
[11] Duvic M, Friedman-Kien AE, Looney DJ, et al. Topical treatment of cutaneous lesions of acquired immunodeficiency syndrome-related Kaposi sarcoma using alitretinoin gel: results of phase 1 and 2 trials.Arch Dermatol, 2000, 136:1461-1469.
[12] Gill PS, McLaughlin T, Espina BM, et al. Phase I study of human chorionic gonadotropin given subcutaneously to patients with acquired immunodeficiency syndrome-related mucocutaneous Kaposi's sarcoma.J Natl Cancer Inst, 1997, 89:1797-1802.
[13] Glesby M J, Hoover DR, Weng S, et al. Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from the Multicenter AIDS Cohort Study. J Infect Dis, 1996, 173:1477-1480.
[14] Mocroft A, Youle M, Gazzard B, et al. Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. AIDS, 1996, 10:1101-1105.